NASDAQ:ICAD

iCAD (ICAD) Stock Price, News & Analysis

$1.47
-0.02 (-1.34%)
(As of 05/3/2024 ET)
Today's Range
$1.45
$1.50
50-Day Range
$1.41
$2.27
52-Week Range
$1.05
$3.97
Volume
62,830 shs
Average Volume
183,883 shs
Market Capitalization
$38.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

iCAD MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
240.1% Upside
$5.00 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.61 out of 5 stars

Computer And Technology Sector

3247th out of 3,570 stocks

Surgical & Medical Instruments Industry

511th out of 570 stocks

ICAD stock logo

About iCAD Stock (NASDAQ:ICAD)

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

ICAD Stock Price History

ICAD Stock News Headlines

Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
ICAD Apr 2024 2.500 call
ICAD Apr 2024 2.500 put
Q4 2023 ICAD Inc Earnings Call
icad: Q4 Earnings Insights
icad earnings preview: what Wall Street is expecting
See More Headlines
Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
5/03/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ICAD
Employees
67
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+235.6%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-4,850,000.00
Pretax Margin
-40.36%

Debt

Sales & Book Value

Annual Sales
$17.32 million
Book Value
$1.27 per share

Miscellaneous

Free Float
23,217,000
Market Cap
$39.29 million
Optionable
Optionable
Beta
1.36

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Dana R. Brown (Age 59)
    President, CEO & Executive Chair
  • Mr. Jonathan GoMr. Jonathan Go (Age 61)
    Chief Technology Officer
    Comp: $351.89k
  • Mr. Eric Lonnqvist
    Chief Financial Officer
  • Ms. Michelle Strong
    Chief Operations Officer
  • Ms. Annette L. Heroux (Age 67)
    Vice President of Administration
    Comp: $174.9k
  • Brian Testa
    Chief People Officer
  • Mr. Bill Keyes
    Senior VP of Global Sales Operations
  • Mr. Vasu Avadhanula
    Chief Product Officer
  • Mr. Peter Graham
    Senior VP of North American Sales

ICAD Stock Analysis - Frequently Asked Questions

What is iCAD's stock price target for 2024?

0 Wall Street research analysts have issued 1-year price targets for iCAD's shares. Their ICAD share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price.
View analysts price targets for ICAD
or view top-rated stocks among Wall Street analysts.

How have ICAD shares performed in 2024?

iCAD's stock was trading at $1.77 on January 1st, 2024. Since then, ICAD shares have decreased by 16.9% and is now trading at $1.47.
View the best growth stocks for 2024 here
.

Are investors shorting iCAD?

iCAD saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 451,300 shares, an increase of 9.2% from the March 15th total of 413,100 shares. Based on an average daily volume of 210,300 shares, the short-interest ratio is currently 2.1 days. Approximately 1.8% of the company's shares are sold short.
View iCAD's Short Interest
.

When is iCAD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our ICAD earnings forecast
.

How can I listen to iCAD's earnings call?

iCAD will be holding an earnings conference call on Wednesday, May 15th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) announced its earnings results on Tuesday, March, 12th. The technology company reported ($0.02) EPS for the quarter. The technology company had revenue of $4.74 million for the quarter. iCAD had a negative trailing twelve-month return on equity of 21.63% and a negative net margin of 27.08%.

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD Chief Executive Officer Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among the company's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

Who are iCAD's major shareholders?

iCAD's stock is owned by many different institutional and retail investors. Top institutional shareholders include Salem Investment Counselors Inc. (0.28%). Insiders that own company stock include Andy Sassine, Charles Ross Carter, Dana R Brown, Jonathan Go, Michael S Klein, Stacey M Stevens, Susan Alyson Wood and Timothy Norris Irish.
View institutional ownership trends
.

How do I buy shares of iCAD?

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICAD) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners